NCT04467723View on ClinicalTrials.gov

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

August 31, 2027

Conditions
NSCLC Stage IVNSCLC, Recurrent
Interventions
DRUG

Atezolizumab

Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30

Trial Locations (2)

66205

NOT_YET_RECRUITING

The University of Kansas Cancer Center (KUCC), Fairway

RECRUITING

The University of Kansas Cancer Center, Westwood Campus, Kansas City

All Listed Sponsors
collaborator

parkview cancer institute

UNKNOWN

lead

University of Kansas Medical Center

OTHER